ArticleJournal of public health dentistry2026
Trend Analysis of Medically Related Osteonecrosis of the Jaw in the United States Using US National Inpatient Data From 2016 to 2022.
Article in Journal of public health dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study presents a trend analysis of Medication-Related Osteonecrosis of the Jaw (MRONJ) using US National Inpatient Sample (NIS) data from 2016 to 2022, providing insights into its epidemiology, comorbidities, and economics.
methodsA retrospective cross-sectional analysis was performed using US MRONJ hospital admissions. Prevalence rates were calculated relative to Bisphosphonate patient numbers in the United States and hospital-based denominators. Statistical analyses included two-sample proportion (Z) tests, Cochran-Armitage trend tests, Welch t-tests, and multivariable linear and ANOVA models with false discovery rate (FDR) correction for multiple comparisons, effect sizes, market basket analysis.
resultsCochran-Armitage trend tests revealed significant increasing trends in MRONJ prevalence across all denominators: total NIS hospitalizations (p = 0.037), dental-related hospitalizations (p = 0.012), and bisphosphonate-exposed patients (p < 0.001). Females were more affected with MRONJ than males consistently across all years (p = 0.188). Whites had the highest number of cases across all years (p = 0.774). No region or income bracket stood out as highest or lowest. Medicare is the primary payer with 61%-80% of patients covered (p = 0.497). The average age of patients is around 70 years across all years. The average length of stay in the hospital ranged from 4 to 8 days and the average daily charges ranged from $15,000 to $20,000. Hypertension is the most common co-morbidity (except 2018).
conclusionThe study highlights the incidence of MRONJ, its demographic disparities, economics, and the need for enhanced prevention and cost-effective management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.